Adial Pharmaceuticals, Inc.
ADIL
$1.97
$0.147.65%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.47% | -4.49% | -5.16% | 1.50% | -10.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.85% | -3.36% | 14.14% | 34.69% | 20.27% |
| Operating Income | 5.85% | 3.36% | -14.14% | -34.69% | -20.27% |
| Income Before Tax | 39.55% | 38.21% | 30.66% | 20.37% | -88.48% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 39.55% | 38.21% | 30.66% | 20.37% | -88.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 39.55% | 38.29% | 30.97% | -2.94% | -157.60% |
| EBIT | 5.85% | 3.36% | -14.14% | -34.69% | -20.27% |
| EBITDA | 5.85% | 3.36% | -14.14% | -34.69% | -20.28% |
| EPS Basic | 80.48% | 76.65% | 74.39% | 49.61% | 8.01% |
| Normalized Basic EPS | 80.48% | 76.61% | 74.18% | 70.35% | 35.70% |
| EPS Diluted | 80.48% | 76.65% | 74.39% | 49.61% | 8.10% |
| Normalized Diluted EPS | 80.48% | 76.61% | 74.18% | 70.35% | 35.70% |
| Average Basic Shares Outstanding | 243.96% | 198.87% | 176.17% | 202.27% | 239.98% |
| Average Diluted Shares Outstanding | 243.96% | 198.87% | 176.17% | 202.27% | 239.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |